☆ 4.8 Letter

Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function Observations From VERTIS CV

CIRCULATION (2021)

Get Full Text
Add to Collection

Journal

CIRCULATION
Volume 143, Issue 6, Pages 602-605

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.120.051901

Keywords

cardiovascular disease; diabetes mellitus; type 2; diabetic nephropathies; heart failure; kidney diseases; renal insufficiency; chronic

Categories

Cardiac & Cardiovascular Systems Peripheral Vascular Disease

Funding

  1. Merck Sharp Dohme Corp.
  2. Pfizer Inc, New York, NY

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.